KRAS and pancreatic neoplasm: Unlike the MEK inhibitor, the ERK-selective inhibitor SCH772984 did enhance VS-5584-induced cell death in BxPC-3 cells, which is consistent with Hayes and colleagues who reported that SCH772984-sensitive pancreatic cancer cell lines (all KRAS mutants) tended to be resistant to the MEK inhibitor selumetinib [26].